Tjoapack doubles packaging capacity with €10M investment at Netherlands facility
The expansion includes the addition of automated and high-speed production lines.
Tjoapack has doubled packaging capacity with an expansion of its facility in Etten-Leur, Netherlands following an investment of more than €10 million.
The contract packaging organisation (CPO), which specializes in primary and secondary packaging of oral solids and injectables, has added 10 new production rooms and increased the size of its Dutch facility from 8,400sqm to 11,500sqm.
The expansion includes the addition of three new production lines, as well as a fully automated packaging line for vials, with the capacity of packing 12 million vials per year. There are also two new high-speed production lines for oral solids, capable of packing over 500 blisters per minute each.
The expansion brings the total number of packaging lines for blisters, vials and bottles at the facility to 18.
This is the latest investment by Tjoapack following its acquisition of US healthcare packaging firm Pharma Packaging Solutions (PPS) last year.
The company is also said to have plans in the pipeline for a new packaging line for pre-filled syringes and aims to purchase more blister machines which will increase capacity by the end of the year.
Tjoapack has also recently invested in its warehousing and cold chain capabilities to meet increased customer demand for its added value logistics services.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.